Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer

TOP - November 2017, Vol 10, No 4 - Lung Cancer
Phoebe Starr

Chicago, IL—Alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, was called a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer (NSCLC), based on results of the phase 3 ALEX clinical trial, which were presented at the 2017 ASCO annual meeting.

Alectinib prevented disease progression for a median of 15 months or longer, delayed the time to brain metastases, and was associated with fewer side effects compared with crizotinib (Xalkori), the current standard of care, said lead investigator Alice T. Shaw, MD, PhD, Director, Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center, Boston.

“This is the first head-to-head trial to compare a next-generation ALK inhibitor with the standard of care, crizotinib,” said Dr Shaw. “This global study establishes alectinib as the new standard of care for initial treatment in this setting. Alectinib was especially beneficial in controlling and preventing brain metastases, which can have a major impact on patients’ quality of life,” she added.

The majority of patients with ALK mutation–positive NSCLC who receive crizotinib have resistance and disease progression, and the brain is the most common site of disease progression.

Alectinib is a more potent ALK inhibitor than crizotinib and is better able to penetrate the central nervous system (CNS). Alectinib is FDA approved for patients with NSCLC plus ALK mutation that did not respond to crizotinib therapy.

Alectinib for First-Line Treatment

The ALEX clinical trial involved 303 patients with ALK-positive advanced or metastatic NSCLC who did not receive therapy for metastatic disease. Patients were randomized in a 1:1 ratio to alectinib 600 mg twice daily or to crizotinib 250 mg twice daily. Patients with CNS metastases were allowed to participate in the study.

The study met its primary end point of prolonged progression-free survival (PFS). The median PFS was not yet reached with alectinib versus 11.1 months with crizotinib, representing a 53% risk reduction for disease progression (P <.0001). Results were similar in an independent review, with a median PFS of 25.4 months with alectinib versus 10.4 months with crizotinib.

“This represents more than a doubling of progression-free survival,” said Dr Shaw. “Nobody expected it would be possible to delay advanced lung cancer progression by this much. Most targeted therapies for lung cancer are associated with a median progression-free survival of roughly 12 months,” she added.

Alectinib achieved an 84% risk reduction for CNS progression versus crizotinib. Brain metastases were reported in 9% of patients in the alectinib group versus 41% in the crizotinib group.

Alectinib therapy was associated with fewer side effects versus crizotinib therapy. The rate of grade 3 to 5 adverse events was 41% with alectinib and 50% with crizotinib. In addition, patients who received alectinib had fewer treatment interruptions, dose reductions, or discontinuations versus patients who received crizotinib.

Results of the ALEX study were greeted with enthusiasm at a press conference. “This is a watershed moment in the treatment of ALK-positive NSCLC. Often, studies show only incremental improvements with a new treatment. This is different. Alectinib shows a dramatic increase in efficacy that is also accompanied by better tolerability,” stated ASCO expert John V. Heymach, MD, PhD, Chairman, Department of Thoracic/Head and Neck Medical Oncology, M.D. Anderson Cancer Center, Houston.

“I firmly agree with Dr Shaw. This is a new standard of care for first-line ALK-positive lung cancer,” said Dr Heymach.

Related Items
Pembrolizumab Makes Inroads in Sarcoma Subtypes
Phoebe Starr
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Immunotherapy, Online First
Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Breast Cancer
Osimertinib Extends Progression-Free Survival in EGFR T790M–Positive Lung Cancer with CNS Metastases Myeloma
Wayne Kuznar
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Lung Cancer
Novel Drug “Home Run” for TRK Mutation–Positive Tumors
Phoebe Starr
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Emerging Therapies
Dacomitinib Represents Potential New Targeted Therapy for EGFR Mutation–Positive Lung Cancer
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Lung Cancer
Healthy Lifestyle Improves Survival in Patients with Colon Cancer
Phoebe Starr
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Colorectal Cancer, Conference Correspondent
8-Week Internet-Based Psychological Intervention Reduces Stress in Patients Newly Diagnosed with Cancer
Phoebe Starr
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
More Support for Regular Use of Low-Dose Aspirin
Phoebe Starr
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Cardiotoxicity with Targeted Therapies Is Rare, but Requires Attention
Phoebe Starr
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Immunotherapy
Last modified: November 21, 2017